

Scancell Holdings plc
("Scancell" or the "Company")

Notice of Interim Results and Investor Presentation

Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, will announce its interim financial results for the six months ended 31 October 2025 and provide a business update on progress achieved post-period, on Thursday 29 January 2026.

Phillip L'Huillier, Chief Executive Officer, and Sath Nirmalanathan, Chief Financial Officer, will host a live webcast for analysts and investors on the day of the results at 14:00 GMT.

If you would like to join the webcast, please follow this link:

[Interim Financial Results for the six months ending 31 October 2025 | SparkLive | LSEG](#)

For further information, please contact:

Scancell Holdings plc +44 (0) 20 3709 5700

Phillip L'Huillier, CEO

Dr Jean-Michel Cosséry, Non-Executive Chairman

Panmure Liberum Limited (Nominated Advisor and Joint Broker) +44 (0) 20 7886 2500

Emma Earl/ Will Goode, Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

WG Partners LLP (Joint Broker) +44 (0) 20 3705 9330

David Wilson, Claes Spang

Investor and media relations

Mary-Ann Chang +44 (0) 20 7483 284853

MaryAnnChang@scancell.co.uk

Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent and long-lasting tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+, an Immunobody® active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+, in combination with CPIs bring benefit has been identified – enabling a precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.